Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Benzethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.98 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | TSHR | P16473 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | APAF1 | O14727 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | RAD52 | P43351 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzethonium SCHEMBL122985 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL21713 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL1672928 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL1282115 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL4418328 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL1951703 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL27797280 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL5549294 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL22711570 | 0.98 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 | |
| Benzethonium SCHEMBL7271857 | 0.97 | SMN1; SMN2 (0.98) | SMN1; SMN2HIF1ALMNAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340726-A | Aqueous suspension composition containing sirolimus or salt thereof | 参天制药株式会社 | 2024-07-16 | — | — | CN | claimed |
| CN-114845714-B | Aqueous suspension composition containing sirolimus or salt thereof | 参天制药株式会社 | 2024-05-14 | — | — | CN | claimed |
| CN-117858620-A | Antimicrobial combinations | 西姆莱斯有限公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2024015764-A1 | 3,5-DIIODOTHYROPROPIONIC ACID COMPOSITIONS AND METHODS OF USE THEREOF | PriZm, LLC (US) | 2024-01-18 | — | — | WO | claimed |
| US-20240009157-A1 | 3,5-DIIODOTHYROPROPIONIC ACID COMPOSITIONS AND METHODS OF USE THEREOF | DEXCEL PHARMA TECHNOLOGIES LTD. (IL) | 2024-01-11 | — | — | US | claimed |
| CN-116445426-A | Composition capable of inactivating coronavirus based on nine-component-Emei extract and application thereof | 肖玮双 | 2023-07-18 | — | — | CN | claimed |
| CN-116122057-A | High-strength cold-resistant textile for aerospace use and manufacturing method thereof | 西京学院 | 2023-05-16 | — | — | CN | claimed |
| CN-107750124-B | Antimicrobial compositions and methods for reducing microbial contamination | 波利维逊有限公司 | 2022-10-28 | — | — | CN | claimed |
| US-20220313598-A1 | Antimicrobial Compositions and Methods For Reducing Microbial Contamination | POLYVATION B.V. (NL) | 2022-10-06 | — | — | US | claimed |
| US-11291625-B2 | Antimicrobial compositions and methods for reducing microbial contamination | POLYVATION B.V. (NL) | 2022-04-05 | — | — | US | claimed |
| US-20170216196-A1 | SILDENAFIL SUBLINGUAL SPRAY FORMULATIONS | BENUVIA OPERATIONS, LLC | 2017-08-03 | — | — | US | claimed |
| US-20170216199-A1 | EPINEPHRINE SPRAY FORMULATIONS | HIKMA PHARMACEUTICALS USA INC. | 2017-08-03 | — | — | US | claimed |
| US-9662334-B2 | Sildenafil sublingual spray formulations | INSYS DEVELOPMENT COMPANY, INC. (US) | 2017-05-30 | — | — | US | claimed |
| WO-2016178578-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR REDUCING MICROBIAL CONTAMINATION | POLYVATION B.V. (NL) | 2016-11-10 | — | — | WO | claimed |
| WO-2016161397-A1 | SILDENAFIL SUBLINGUAL SPRAY FORMULATIONS | INSYS DEVELOPMENT COMPANY, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20160287593-A1 | SILDENAFIL SUBLINGUAL SPRAY FORMULATIONS | BENUVIA OPERATIONS, LLC | 2016-10-06 | — | — | US | claimed |
| US-20090324737-A1 | Antimicrobial And Sporicidal Composition | PHARMULATIONS, L.C. | 2009-12-31 | — | — | US | claimed |
| US-20080095861-A1 | Antimicrobial and sporicidal composition | PHARMULATIONS, L.C. | 2008-04-24 | — | — | US | claimed |
| US-20040058878-A1 | Antimicrobial and sporicidal composition | PHARMULATIONS, L.C. | 2004-03-25 | — | — | US | claimed |
| WO-2003061610-A1 | ANTIMICROBIAL AND SPORICIDAL COMPOSITION | WALKER EDWARD B (US) | 2003-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216199-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRA2C, ADRB3, ADRB2 | CHRM2 169/4885CHRM4 304/4885CHRM5 72/4885 |
| US-11291625-B2 | Antimicrobial compositions and methods for reducing microbial contamination | CUTA, VNN1, NACA | CHRM2 4794/4885CHRM4 4690/4885CHRM5 4477/4885 |
| US-20220313598-A1 | Antimicrobial Compositions and Methods For Reducing Microbial Contamination | CUTA, VNN1, NACA | CHRM2 4794/4885CHRM4 4690/4885CHRM5 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.